Table 5.
Added predictive value of biomarkers over already known predictors for mean yearly radiographic progression rate over 5 years of treatment
| Item | B | 95% CI | Standardized beta | P | R 2 |
|---|---|---|---|---|---|
| Intercept | 0.54 | 0.12 to 0.96 | 0.013 | ||
| Treatment strategy | 0.13 | -0.16 to 0.43 | 0.08 | 0.375 | 0.000 |
| RF positive | 0.29 | -0.02 to 0.60 | 0.15 | 0.063 | 0.029 |
| Baseline joint damage | 0.09 | 0.06 to 0.13 | 0.44 | 0.000 | 0.211 |
| EULAR good responsea | -0.36 | -0.78 to 0.07 | -0.20 | 0.100 | |
| EULAR moderate responsea | -0.13 | -0.52 to 0.27 | -0.07 | 0.534 | 0.229 |
| C1,2C change from 1 yr to baseline | -1.11 | -1.87 to -0.36 | -0.24 | 0.004 | 0.283 |
aEULAR nonresponse was used as reference category. 95% CI, 95% confidence interval; RF, rheumatoid factor.